The ARG1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 143B human osteosarcoma cell line, designed to disrupt the ARG1 gene encoding arginase-1. This polyclonal model provides a heterogeneous pool of genetically edited cells without clonal selection, enabling functional studies of ARG1 loss while preserving the biological variability inherent to the parental 143B line.
The parental 143B cell line is a highly tumorigenic and metastatic subline of HOS, established from a human osteosarcoma. As a malignant bone-forming cell line, 143B is extensively utilized in cancer research for its aggressive growth characteristics and robust metastatic capacity in xenograft models. Its well-characterized behavior makes it an ideal host for generating knockout models to investigate oncogenic mechanisms and tumor?Chost interactions.
Arginase-1 (ARG1) catalyzes the hydrolysis of L-arginine to L-ornithine and urea, a key reaction in the urea cycle. In the tumor microenvironment, ARG1 competes with nitric oxide synthase (NOS) for arginine, modulating nitric oxide production. ARG1 expression is regulated by IL-4 and IL-13 via STAT6, and also by TGF-??, C/EBP??, and cAMP. The resulting ornithine feeds into polyamine biosynthesis through ornithine decarboxylase (ODC) and spermidine synthase, and into proline synthesis, promoting proliferation. Importantly, ARG1-mediated arginine depletion suppresses T-cell receptor signaling, impairing T-cell function and enabling immune evasion??a mechanism relevant to osteosarcoma.
In 143B osteosarcoma cells, ARG1-driven arginine depletion may facilitate immune escape by blunting T-cell responses, while diversion into polyamines and proline supports tumor growth and metastasis. Knockout of ARG1 in this aggressive model allows dissection of its metabolic and immunomodulatory roles. The polyclonal knockout population enables assessment of collective functional impacts on proliferation, migration, and tumor?Cimmune interactions, both in vitro and in vivo.
This model is suited for applications including arginine metabolism studies, tumor immune evasion research, osteosarcoma progression analysis, and arginase inhibitor screening. Representative assays include arginase activity assays, urea/ornithine quantification, polyamine profiling, T-cell suppression co-culture, cell proliferation/migration assays, western blotting, RT-qPCR, and xenograft tumor models. For further information or technical support, contact Ascent Research.
